Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis

Conditions

• Primary Disease
• Pulmonary Alveolar Proteinosis

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• rituximab — DRUG
  IV, 1000 mg, two weeks, 2 times

Study Details

The purpose of this study is to determine whether the use of rituximab is effective in treating pulmonary alveolar proteinosis by leading to an improvement in lung function and disease status.

Key Dates

Start date

Jan 31, 2007

Status verified

Sep 2023

Primary completion

Jul 31, 2009

Completion

Dec 31, 2011

Study Design

Enrollment

10 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: 1

Primary Outcome Measure

Evaluate symptomatic, physiologic and radiographic effects of therapy [ Time Frame: 6-months ]

Locations (1)

Find similar trials in Greenville, NC

Related Studies

• A National Registry For Pulmonary Alveolar Proteinosis
  Recruiting · Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio